Dry eye disease - Epidemiology Forecast - 2034

Dry eye disease - Epidemiology Forecast - 2034

Key Highlights

In 2023, the total diagnosed prevalence of Dry eye disease (DED) was highest in the US among the 7MM, accounting for nearly 22,475 thousand cases which is further expected to increase by 2034.

In Japan, in 2023, ~2,341 thousand males and ~ 8,298 thousand females were affected with Dry eye disease (DED). DelveInsight estimates that these numbers might increase by 2034.

In 2023, the UK reported ~2,811 thousand mild, ~1,345 thousand moderate, and ~1,956 thousand severe cases of DED. Analysis by DelveInsight’s experts indicates that the overall severity-specific cases of DED are expected to rise in the coming years.

The Dry Eye Disease (DED) cases are expanding due to increasing prevalence, rising awareness and better diagnostic capabilities, which increase demand for treatments. Advancements in research, increased funding for rare diseases, and the development of novel therapies are also key drivers.

As per DelveInsight’s estimates, Japan accounted for nearly 19% of the Total Diagnosed Prevalent Cases of Dry Eye Disease (DED) in the 7MM in 2023.

DelveInsight’s “Dry Eye Disease (DED) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of Dry Eye Disease (DED), historical and forecasted epidemiology of Dry Eye Disease (DED) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

The United States

EU4 (Germany, France, Italy, and Spain) and the United Kingdom

Japan

Study Period: 2020–2034

Dry Eye Disease (DED) Disease Understanding

Dry Eye Disease (DED) Overview

DED, which is also known as dry eye disease or keratoconjunctivitis sicca, is a multifactorial disease of the ocular surface due to a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities.

The most common cause of DED is hormonal changes which lead to poor functioning of the tear glands and reduced secretion of tears.

Dry Eye Disease (DED) Diagnosis

Diagnosing DED involves a comprehensive eye examination, including an assessment of symptoms, tear production, and eye surface health. Various diagnostic tests may be used, such as the Schirmer's test to measure tear production, tear breakup time to assess tear film stability, and ocular surface staining with dyes to detect damage. Additionally, a thorough medical history and evaluation of contributing factors like medications or environmental conditions are essential for an accurate diagnosis.

Despite advancements in DED diagnosis, significant unmet needs still persist. Many patients experience delays due to lack of standardized diagnostic criteria and reliance on subjective symptoms. Enhanced diagnostic tools and more precise, objective measures are crucial to improve early detection, accurately gauge disease severity, and tailor effective treatment strategies, ultimately reducing patient discomfort and healthcare burden.

Further details related to diagnosis are provided in the report…

Dry Eye Disease (DED) Epidemiology

For the purpose of designing the patient-based model for the Dry Eye Disease (DED) epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of DED, Gender-specific Diagnosed Prevalent Cases of DED, Age-specific Diagnosed Prevalent Cases of DED, and Severity-specific Diagnosed Prevalent Cases of DED in the 7MM covering, the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, and Japan from 2020 to 2034.

In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of DED in the 7MM were nearly 54,695 thousand in 2023.

Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of DED with ~6,112 thousand cases, followed by Germany, which had diagnosed prevalent population of ~5,004 thousand in 2023. On the other hand, Spain had the lowest prevalent population (2,064 thousand cases).

The US reported the highest number of total diagnosed prevalent cases of DED among the 7MM countries with 41% whereas Japan reported the least cases (19%). This trend is anticipated to be followed during the forecast period as well.

In the US, gender-specific diagnosed prevalent cases of DED revealed ~9,439 thousand cases among males and approximately ~13,035 thousand cases among females. Projections indicate that by 2034, the prevalence among females will surpass that of males.

DelveInsight's analysis shows that the UK reported the highest number of DED cases in individuals aged 50 and older, with ~4,889 thousand cases. This was followed by ~691 thousand cases in the 40-49 age group and ~532 thousand cases in the 18-39 age group. Projections indicate that the UK is expected to continue leading in these figures by 2034.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the Harvard Medical School, Boston, Massachusetts, US University of Pikeville, Kentucky College of Optometry, Pikeville, Kentucky, US; Magdeburg-Stendal University of Applied Sciences, Stendal, Sachsen-Anhalt, Germany; Department of Ophthalmology, Dijon University Hospital, Dijon, France; University of Milan, Milan, Italy; Optometry and Vision Science, Aston University, Birmingham, UK and Ryogoku Eye Clinic, Tokyo, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

The report covers a segment of key events, an executive summary, descriptive overview of Dry Eye Disease (DED), explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.

Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.

The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.

A detailed review of current challenges in establishing the diagnosis.

Dry Eye Disease (DED) Report Insights

Patient Population

Country-wise Epidemiology Distribution

Total Diagnosed Prevalent Cases of DED

Gender-specific Diagnosed Prevalent Cases of DED

Age-specific Diagnosed Prevalent Cases of DED

Severity-specific Diagnosed Prevalent Cases of DED

Dry Eye Disease (DED) Report Key Strengths

11 years Forecast

The 7MM Coverage

Dry Eye Disease (DED) Epidemiology Segmentation

Dry Eye Disease (DED) Report Assessment

Current Diagnostic Practices Patient Segmentation

Epidemiology Insights

What are the disease risk, burdens, and unmet needs of Dry Eye Disease (DED)? What will be the growth opportunities across the 7MM concerning the patient population of Dry Eye Disease (DED)?

What is the historical and forecasted Dry Eye Disease (DED) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?

Why is the diagnosed prevalent cases of Dry Eye Disease (DED) in Japan lower than the US?

Which country has a high patient share for Dry Eye Disease (DED)?

Reasons to Buy

Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.

To understand the Dry Eye Disease (DED) prevalence cases in varying geographies over the coming years.

A detailed overview of Gender and Age Grade-specific diagnosed prevalence of Dry Eye Disease (DED), along with diagnosed prevalence of Dry Eye Disease (DED) Based on severity of airflow limitation and diagnosed prevalence of Dry Eye Disease (DED) based on symptoms and exacerbation history.

To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.

Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Dry Eye Disease (DED) Epidemiology report for the 7MM covers the forecast period from 2024 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Dry Eye Disease (DED) cases in 2023?

The highest cases of Dry Eye Disease (DED) was found in the Germany among EU4 and the UK in 2023.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Dry Eye Disease (DED) cases in 2023?

The highest cases of Dry Eye Disease (DED) were found in the US among the 7MM in 2023.